These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28249992)

  • 1. Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome.
    González López-Valcárcel B; Librero J; García-Sempere A; Peña LM; Bauer S; Puig-Junoy J; Oliva J; Peiró S; Sanfélix-Gimeno G
    Heart; 2017 Jul; 103(14):1082-1088. PubMed ID: 28249992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
    He X; Wang Y; Cong H; Lu C; Wu J
    Clin Ther; 2019 Mar; 41(3):456-465.e2. PubMed ID: 30770126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
    Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.
    Choudhry NK; Brennan T; Toscano M; Spettell C; Glynn RJ; Rubino M; Schneeweiss S; Brookhart AM; Fernandes J; Mathew S; Christiansen B; Antman EM; Avorn J; Shrank WH
    Am Heart J; 2008 Jul; 156(1):31-6. PubMed ID: 18585494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
    J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adherence to medication after myocardial infarction and its impact on outcome: a registry-based analysis from the Hungarian Myocardial Infarction Registry].
    Jánosi A; Ofner P; Kiss Z; Kiss L; Kiss RG; Dinnyés J; Járai Z; Nagy G; Veress G; Ferenci T
    Orv Hetil; 2017 Jul; 158(27):1051-1057. PubMed ID: 28670984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome.
    Allen LaPointe NM; Ou FS; Calvert SB; Melloni C; Stafford JA; Harding T; Peterson ED; Alexander KP
    Am Heart J; 2011 May; 161(5):855-63. PubMed ID: 21570514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term adherence with cardiovascular drug regimens.
    Kulkarni SP; Alexander KP; Lytle B; Heiss G; Peterson ED
    Am Heart J; 2006 Jan; 151(1):185-91. PubMed ID: 16368315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after discharge.
    Hoang C; Kolenic G; Kline-Rogers E; Eagle KA; Erickson SR
    Pharmacotherapy; 2011 Oct; 31(10):927-33. PubMed ID: 21950639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full coverage for preventive medications after myocardial infarction.
    Choudhry NK; Avorn J; Glynn RJ; Antman EM; Schneeweiss S; Toscano M; Reisman L; Fernandes J; Spettell C; Lee JL; Levin R; Brennan T; Shrank WH;
    N Engl J Med; 2011 Dec; 365(22):2088-97. PubMed ID: 22080794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.